Research graph
References from Lanreotide for Advanced Pheochromocytoma and Paraganglioma: Results of a Multicenter Phase II Trial. Local targets link to admitted publications; unresolved targets remain external evidence.
Approach to the patient with metastatic pheochromocytoma and paraganglioma: advances in systemic therapy
10.1210/clinem/dgag182 · 2026 · External reference
10.3390/cancers17223702
10.3390/cancers17223702 · External reference
10.1016/s0140-6736(23)02554-0
10.1016/s0140-6736(23)02554-0 · External reference
Belzutifan for Advanced Pheochromocytoma or Paraganglioma
10.1056/nejmoa2504964 · 2025 · External reference
Single agent axitinib in the management of patients with progressive pheochromocytoma and paraganglioma
10.1200/jco.2024.42.16_suppl.4602 · 2024 · External reference
Phase II Study of (177)Lu-DOTATATE for Progressive Metastatic Pheochromocytomas and Paragangliomas: Interim Analysis of Efficacy, Safety, and Biomarkers
10.1200/jco-25-00791 · 2025 · External reference
10.2967/jnumed.125.270481
10.2967/jnumed.125.270481 · External reference
Metastatic Pheochromocytoma and Paraganglioma: Somatostatin Receptor 2 Expression, Genetics, and Therapeutic Responses
10.1210/clinem/dgad166 · 2023 · External reference
Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World
10.3389/fendo.2021.625312 · 2021 · External reference
10.1016/j.humpath.2018.11.020
10.1016/j.humpath.2018.11.020 · External reference
10.1016/j.humpath.2014.11.012
10.1016/j.humpath.2014.11.012 · External reference
10.1158/1078-0432.ccr-15-1073
10.1158/1078-0432.ccr-15-1073 · External reference
Unresolved reference
External reference
10.1056/nejmoa1316158
10.1056/nejmoa1316158 · External reference
Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline
10.1200/jco.23.01529 · 2023 · External reference
10.1002/onco.13669
10.1002/onco.13669 · External reference
Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: The phase 2 non-randomized SUTNET clinical trial
10.1016/j.ejca.2024.114276 · 2024 · External reference
Safety and efficacy of peptide receptor radionuclide therapy in patients with advanced pheochromocytoma and paraganglioma: A single-institution experience and review of the literature
10.1111/jne.13349 · 2023 · External reference
Potentially fatal crisis after (177)Lu-DOTATATE therapy for paraganglioma: a case report with review of literature
10.1507/endocrj.ej24-0713 · 2025 · External reference
Responses to systemic therapy in metastatic pheochromocytoma/paraganglioma: a retrospective multicenter cohort study
10.1093/ejendo/lvad146 · 2023 · External reference
